HC Wainwright Reiterates Buy Rating for Longboard Pharmaceuticals (NASDAQ:LBPH) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $20.11, but opened at $20.80. Longboard Pharmaceuticals shares last traded at $20.52, with a volume of 36,001 shares changing hands. Analyst Upgrades and Downgrades LBPH has been the topic of several analyst […]
Citigroup began coverage on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research report sent to investors on Friday, Marketbeat reports. The firm issued a buy rating and a $40.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald raised their price objective […]
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) – Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Longboard Pharmaceuticals in a research report issued to clients and investors on Tuesday, July 11th. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.11) per share for the year. The […]
23.02.2023 - Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a .